Goldman Sachs Group Inc. Sells 9,447 Shares of XOMA Royalty Corporation $XOMA

Key Points

• Goldman Sachs Group Inc. reduced its stake in XOMA Royalty Corporation by 45.1%, selling 9,447 shares and now holding 11,523 shares worth approximately $230,000.
• Several analysts upgraded their ratings on XOMA Royalty, with Wall Street Zen and Zacks Research moving from "hold" to "buy" and "strong-buy," respectively, and setting an average price target of $69.50.
• XOMA Royalty reported earnings per share of $0.48, significantly surpassing analysts' expectations of ($0.12), alongside revenues of $13.13 million for the quarter.

Goldman Sachs Group Inc. cut its position in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 45.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,523 shares of the biotechnology company's stock after selling 9,447 shares during the period. Goldman Sachs Group Inc. owned about 0.10% of XOMA Royalty worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Woodline Partners LP boosted its holdings in XOMA Royalty by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock worth $3,359,000 after buying an additional 12,284 shares during the period. Stonepine Capital Management LLC raised its holdings in XOMA Royalty by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock valued at $2,587,000 after acquiring an additional 4,113 shares during the period. Nuveen LLC purchased a new position in shares of XOMA Royalty in the first quarter valued at about $286,000. Deutsche Bank AG boosted its stake in shares of XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after acquiring an additional 6,309 shares during the period. Finally, CM Management LLC boosted its stake in shares of XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock worth $1,276,000 after acquiring an additional 9,000 shares during the period. 95.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen raised XOMA Royalty from a "hold" rating to a "buy" rating in a research note on Monday, August 11th. Zacks Research upgraded shares of XOMA Royalty from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, XOMA Royalty has an average rating of "Buy" and an average price target of $69.50.

XOMA Royalty Stock Up 2.7%

Shares of XOMA opened at $36.68 on Monday. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88. The stock has a market capitalization of $443.46 million, a price-to-earnings ratio of -23.66 and a beta of 0.98. XOMA Royalty Corporation has a 1 year low of $18.35 and a 1 year high of $38.48. The business's 50 day simple moving average is $31.94 and its 200-day simple moving average is $26.67.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The firm had revenue of $13.13 million during the quarter, compared to analyst estimates of $9.39 million. As a group, equities analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other XOMA Royalty news, CFO Thomas M. Burns sold 4,330 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the sale, the chief financial officer directly owned 30,079 shares of the company's stock, valued at $1,082,543.21. The trade was a 12.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.20% of the company's stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.